Danaher Corp. recently expressed interest in a deal for General Electric Co.’s life-sciences business, but GE didn’t engage and isn’t pursuing a deal, according to people familiar with the matter. The structure and value of the proposed transaction couldn’t be determined, and the people said there are no active discussions. GE’s life-sciences business, which had about $4.6 billion in revenue last year, sells lab supplies such as blood-collection kits as well as equipment for biotechnology drug production and research.

Source: Wall Street Journal April 25, 2018 20:00 UTC